Rubicon Research Limited enters its Q1 FY27 results following a year of sequential revenue acceleration and the recent acquisition of Arinna Lifesciences. Investors will be focused on the company's ability to maintain its 22–23% operating EBITDA margin guidance while managing gross margin pressure caused by ongoing reliance on outsourced manufacturing.
| Results date | August 14, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Previous quarter revenue | Rs. 513.9 Cr |
| Previous quarter PAT | Rs. 76.8 Cr |
| Previous quarter EBITDA margin | 23.6% |
| Market cap | Rs. 26,827.76 Cr |
| CMP | Rs. 1620.7 |
The board meeting to consider the unaudited financial results and recommend dividend for FY2027 is scheduled for August 14, 2026.
The investor conference call is scheduled for August 14, 2026, at 6 PM IST, featuring CEO Parag Sancheti, CFO Nitin Jajodia, and SVP Sagar Oak.
Rubicon Research enters Q1 FY27 with strong momentum, having posted Rs. 513.9 Cr in revenue during Q4 FY26, supported by a 4–5% sequential tailwind from INR depreciation against the USD. Gross margins are expected to remain in the 64–66% range as the company continues to rely on outsourced manufacturing while awaiting the commercialization of the Pithampur facility in Q1 CY27. Operating EBITDA margin is likely to remain within the guided 22–23% band, consistent with the company's performance in Q4 FY26 where it achieved a 23.1% operating EBITDA margin. R&D expenditure is tracking toward the Rs. 500 Cr nine-quarter target, with Rs. 193.5 Cr already deployed through the end of FY26. The upcoming call will likely focus on the status of the Pithampur facility following the June-July 2026 US FDA inspection and the initial integration progress of the newly acquired Arinna Lifesciences business.
Performance vs Guidance Tracking: Monitoring key operational commitments against stated targets.
Pithampur facility status: Operational updates following the recent regulatory inspection.
Arinna Lifesciences integration: Early operational metrics from the Indian CNS market entry.
Risks and headwinds to monitor: External factors impacting quarterly performance.
The US FDA issued a Form 483 with two procedural observations following an inspection from June 29 to July 3, 2026. Management maintains that these observations are unrelated to data integrity and expects commercialization to proceed in Q1 CY27.
Gross margins have been pressured by an increased reliance on outsourced manufacturing due to capacity constraints in certain dosage forms. Management expects margins to return to the 67–68% range once the Pithampur facility ramps up production.
The acquisition provides Rubicon with an entry into the Indian CNS market, supported by an existing 4,000-prescriber infrastructure. Management is committed to using this platform to beat Indian Pharmaceutical Market growth by FY28.